Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of medicine for treating virus infection of respiratory system

A technology for respiratory system and viral infection, applied in the direction of respiratory system diseases, antiviral agents, drug combinations, etc., can solve irreversible anemia, persistent incidence of respiratory system viral infection, leukopenia and other problems

Inactive Publication Date: 2007-07-11
WUHAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, many antiviral drugs have limited their clinical application due to toxic side effects and long-term drug resistance: for example, amantadine and its structural derivative methylamantadine, which are commonly used in clinical treatment of influenza, have neurotoxicity and are prone to Drug-resistant strains and ineffectiveness against influenza B virus and other defects; currently the only drug approved by the FDA for the prevention and treatment of respiratory syncytial virus infection is ribavirin, but it has bone marrow cytotoxicity when it is administered intravenously, and it is passed through aerosol. Leukopenia occurs when the respiratory tract is administered in a small amount, and side effects such as headache and irreversible anemia can be caused when the dose is too large; thus, the incidence of respiratory virus infection continues to persist

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of medicine for treating virus infection of respiratory system
  • Use of medicine for treating virus infection of respiratory system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1: Arbidol hydrochloride is to the protective effect of infection coxsackie virus B3 animal

[0017] BalB / C mice, both male and female, were randomly divided into 6 groups: normal control group, virus control group, positive drug control group, test drug group (using 3 concentrations, namely Arbidol hydrochloride high-dose group, middle-dose group) and low dose group) 27 mice per group. Two days before the infection, the mice in each group of Arbidol hydrochloride were intragastrically administered, twice a day; the positive drug control group was injected intraperitoneally with ribavirin; 2 times. The normal control group was fed naturally without any treatment. On the day of the experiment, after routine disinfection of the infected parts of the mice, intraperitoneal injection of CVB 3 , Continue medication 2 hours after inoculation. Observe the survival rate; when continuous treatment reaches the acute stage, randomly kill 1 / 3 of each group, take the r...

Embodiment 2

[0019] Embodiment 2: Arbidol hydrochloride is to the protective effect of infection Coxsackie virus B5 animal

[0020] Balb / C mice, female, 5-7 weeks old, weighing 17-20g, were randomly divided into 5 groups: normal control group, virus control group, positive drug control group, treatment dose 25mg / kg / d experimental group and treatment Dose 50mg / kg / d experimental group, 10 rats in each group.

[0021] On the day of the experiment, after routine disinfection of the infected parts of the mice, intraperitoneal injection of CVB 5 . 24 hours after virus inoculation, the mice in each group of Arbidol hydrochloride were intragastrically administered, once a day, for 6 consecutive days; the normal control group did not receive any treatment; the virus control group was intragastrically administered with an equal volume of PBS to replace the drug . Six mice in each group were sacrificed on day 8 after virus inoculation. Parts of lung, heart and liver obtained from dissection were ...

Embodiment 3

[0029] Embodiment 3: Arbidol hydrochloride is to the protective effect of adenovirus infection animal

[0030] Mice were randomly divided into 6 groups, 10 mice in each group. They are: normal control group, virus control group, ribavirin group, Arbidol hydrochloride high, medium and low dose groups. The mice were anesthetized with ether, and then infected with adenovirus stock solution by intranasal instillation. After 4 hours, the mice in each group of Arbidol hydrochloride were intragastrically administered, twice a day, for 8 consecutive days; the virus control group was administered daily. The stomach was disinfected twice with drinking water; the normal control group received no treatment; the positive drug ribavirin control group received intraperitoneal injection of drugs. After 8 days of administration, the mice were killed and dissected, and their body weight was weighed with a precision balance; the blood was collected to separate the serum, and the anti-adenovirus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for producing drug that treats virus infection of respiratory tract, wherein it uses Arbidol Hydrochloride as 6-bromine-4-(dimethylamino)-5-hydroxyl group-1-methyl-2-(benzene sulfenyl)-1H-indole-3-glycolate-hydrates. The invention can reduce the mouse dead rate affected by virus B3, B5, adenovirus, etc, and improve antibody level, with wide application.

Description

technical field [0001] The present invention relates to the use of a medicine for treating respiratory system virus infection, in particular to a medicine for treating respiratory system infection caused by Coxsackie virus B3, Coxsackie virus B5, adenovirus, respiratory syncytial virus and rhinovirus infection. Use of medicines for disease. Background technique [0002] Acute respiratory infection is the most common disease in humans, and more than 80% of it is caused by viruses. It is the main cause of morbidity and death in the elderly and children worldwide. There are many types of viruses that cause respiratory infections, among which the more common ones are: influenza virus, respiratory syncytial virus, adenovirus, rhinovirus and some enteroviruses (such as Coxsackie virus). [0003] At present, many antiviral drugs have limited their clinical application due to toxic side effects and long-term drug resistance: for example, amantadine and its structural derivative met...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/404A61P31/14A61P11/00
Inventor 杨占秋罗凡钟琼王又又石丽桥肖红季红
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com